Novartis Inc header image

Novartis Inc

NOVN

Equity

ISIN CH0012005267 / Valor 1200526

SIX Swiss Exchange (2026-07-24)

CHF 126.90-0.60%

Novartis Inc
UMushroom community rating:

3.95 45 votes No rating yet

NegativeNeutralPositive

About company

Novartis Inc. is a global healthcare company that specializes in the development and distribution of innovative medicines. With a focus on addressing unmet medical needs, Novartis aims to improve and extend the lives of people suffering from serious diseases. The company operates in several core therapeutic areas, including cardiovascular, renal and metabolic diseases, immunology, neuroscience, and oncology. Novartis is known for its commitment to research and development, leveraging advanced technology platforms to create groundbreaking therapies. With a workforce of approximately 78,000 employees representing over 140 nationalities, Novartis has a significant global presence, reaching more than 284 million patients worldwide. The company's strategy revolves around delivering high-value medicines and employing novel access approaches to alleviate some of society's most significant disease burdens.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

35.7%1Y

47.5%3Y

58.3%5Y

Performance

19.2%1Y

18.9%3Y

18.3%5Y

Volatility

296004 M

Market cap (USD)

1,859,367

Daily traded volume (Shares)

88.82 / 87.81

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

3.95

45 votes

Performance:

3.58

Innovation:

3.92

Society:

3.88

Nature:

3.43

Oliver Frei

Switzerland, 21 Mar 2026

-

Pavle Stojicic

Switzerland, 20 Mar 2026

Great company, wrong year to expect excitement. Own it in 2027 when the patent cliff is behind them and the new drugs are fully ramping.

Lorenzo Castillejo

Switzerland, 19 Mar 2026

Amazing stock

EQUITIES OF THE SAME SECTOR

Tecan Group Ltd.

Tecan Group Ltd. Valor: 1210019

Annual Return

-50%0%+50%

Risk level

110

1.50%CHF 182.20

Straumann Holding Ltd

Straumann Holding Ltd Valor: 117544866

Annual Return

-50%0%+50%

Risk level

110

-0.50%CHF 96.12

Idorsia Ltd

Idorsia Ltd Valor: 36346343

Annual Return

-50%0%+50%

Risk level

110

1.48%CHF 6.17

Medacta Group Ltd

Medacta Group Ltd Valor: 46852522

Annual Return

-50%0%+50%

Risk level

110

0.77%CHF 130.20

AEVIS VICTORIA SA

AEVIS VICTORIA SA Valor: 47863410

Annual Return

-50%0%+50%

Risk level

110

0.00%CHF 12.95

Max Healthcare Institute Ltd

Max Healthcare Institute Ltd Valor: 45624817

Annual Return

-50%0%+50%

Risk level

110

-0.20%INR 1,081.50

Option Care Health Inc

Option Care Health Inc Valor: 52359365

Annual Return

-50%0%+50%

Risk level

110

2.75%USD 21.66

GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited Valor: 910581

Annual Return

-50%0%+50%

Risk level

110

0.76%INR 2,513.25

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited Valor: 2593348

Annual Return

-50%0%+50%

Risk level

110

1.61%INR 8,000.10

Orion Oyj

Orion Oyj Valor: 2553367

Annual Return

-50%0%+50%

Risk level

110

-0.82%EUR 78.45

SIX

FactSet

Clearbit

Logos provided by Clearbit